Bispecific antibody treatment for the simultaneous activation of immune and anti-cancer cells
AM105 is a bispecific antibody derived from the AffiMab platform that specifically targets EGFR disease protein and immune cells.
AM105 has a dual mode of action for the treatment of cancer. AM105’s first target is
the CD137 (4-1BB) surface protein of immune cells, while its second target is the
EGFR disease protein. AM105 minimizes toxicity by nonspecifically activating immune
cells and can also easily be adapted to treat other cancers by swapping
out the target disease protein.
#1401 285, Digital-ro, Guro-gu, Seoul, Republic of Korea
T. +82-2109-1294 F. +82-2109-1296 E. email@example.com